Literature DB >> 9704225

The Toronto Tri-Hospital Gestational Diabetes Project. A preliminary review.

M Sermer1, C D Naylor, D Farine, A B Kenshole, J W Ritchie, D J Gare, H R Cohen, K McArthur, S Holzapfel, A Biringer.   

Abstract

In this study, we assessed maternal-fetal outcomes in untreated patients with increasing carbohydrate intolerance not meeting the current criteria for the diagnosis of gestational diabetes mellitus (GDM), examined the relationship between birth weight and mode of delivery among women with untreated borderline GDM, treated overt GDM, and normoglycemia, and established more efficient screening strategies for detection of GDM. This was a prospective analytic cohort study in which nondiabetic women aged > or = 24 years were eligible for enrollment. A 50-g glucose challenge test (GCT) and a 100-g oral glucose tolerance test (OGTT) were administered at 26 and 28 weeks gestational age, respectively. Risk factors for unfavorable maternal-fetal outcomes were recorded. Time since the last meal prior to the screening test was recorded, as well. Caregivers and patients were blinded to glucose values except when test results met the National Diabetes Data Group criteria for GDM. Maternal and fetal outcomes, including the mode of the delivery, were recorded in the postpartum period. Of 4,274 patients screened, 3,836 (90%) continued to the diagnostic oral glucose tolerance test. GDM was seen in 145 women. Increasing carbohydrate intolerance in women without overt gestational diabetes was associated with a significantly increased incidence of cesarean section, preeclampsia, macrosomia, and need for phototherapy, as well as an increased length of maternal and neonatal hospital stay. Multivariate analysis showed that increasing carbohydrate intolerance remained an independent predictor for various unfavorable outcomes, but the strength of the associations was diminished. Compared with normoglycemic control subjects, the untreated borderline GDM group had increased rates of macrosomia (28.7 vs. 13.7%, P < 0.001) and cesarean delivery (29.6 vs. 20.2%, P = 0.03). Usual care of known GDM patients normalized birth weights, but the cesarean delivery rate was about 33%, whether macrosomia was present or absent. An increased risk of cesarean delivery among treated patients compared with normoglycemic control subjects persisted after adjustment for multiple maternal risk factors. As for the screening tests, time since the last meal had a marked effect on mean plasma glucose. Receiver operating characteristic curve analysis allowed the selection of the most efficient cut points for the GCT based on the time since the last meal. These cut points were 8.2, 7.9, and 8.3 mmol/l (1 mmol/l = 18.015 mg/dl) for elapsed postprandial time of < 2, 2-3, and > 3 h, respectively. With this change from the current threshold of 7.8 mmol/l, the number of patients with a positive screening test dropped from 18.5 to 13.7%. There was an increase in positive predictive value from 14.4 to 18.7%. The overall rate of patient misclassification fell from 18.0 to 13.1%. In conclusion, increasing maternal carbohydrate intolerance in pregnant women without GDM is associated with a graded increase in adverse maternal and fetal outcomes. Infant macrosomia is an important factor in high cesarean delivery rates for women with untreated borderline GDM. Although detection and treatment of GDM normalizes birth weights, rates of cesarean delivery remain inexplicably high. Recognition of GDM may lead to a lower threshold for surgical delivery. The efficiency of screening for GDM can be enhanced by adjusting the current GCT threshold of 7.8 mmol/l to new values related to time since the last meal before screening. Further analyses are underway to elucidate whether maternal risk factors can be used to achieve additional efficiency gains in screening.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704225

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  24 in total

Review 1.  Screening for diabetes in pregnancy.

Authors:  S Virjee; S Robinson; D G Johnston
Journal:  J R Soc Med       Date:  2001-10       Impact factor: 5.344

2.  Quantitative risk estimation for large for gestational age using the area under the 100-g oral glucose tolerance test curve.

Authors:  Sollip Kim; Won-Ki Min; Sail Chun; Woochang Lee; Hee-Jung Chung; Pil Ryang Lee; Ahm Kim
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Evaluation of oral glucose tolerance test, β-cell function and adverse obstetric outcomes.

Authors:  Hongxiu Zhang; Dongmei Zhao; Jie Shen; Xiaoping Zhou; Wenwei Chen; Shiwen Jiang
Journal:  Biomed Rep       Date:  2013-07-16

4.  Comparison of the criteria forgestational diabetes mellitus by NDDG and Carpenter and Coustan, and the outcomes of pregnancy.

Authors:  A Gokcel; T Bagis; E B Killicadag; E Tarim; N Guvener
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

5.  Potential impact of American Diabetes Association (2000) criteria for diagnosis of gestational diabetes mellitus in Spain.

Authors:  W Ricart; J López; J Mozas; A Pericot; M A Sancho; N González; M Balsells; R Luna; A Cortázar; P Navarro; O Ramírez; B Flández; L F Pallardo; A Hernández; J Ampudia; J M Fernández-Real; R Corcoy
Journal:  Diabetologia       Date:  2005-05-12       Impact factor: 10.122

Review 6.  Controversies around gestational diabetes. Practical information for family doctors.

Authors:  Len Kelly; Laura Evans; David Messenger
Journal:  Can Fam Physician       Date:  2005-05       Impact factor: 3.275

7.  Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study.

Authors:  Suresh Babu Naraharisetti; Brian J Kirby; Mary F Hebert; Thomas R Easterling; Jashvant D Unadkat
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-22       Impact factor: 3.205

8.  Gestational diabetes: risks, management, and treatment options.

Authors:  Catherine Kim
Journal:  Int J Womens Health       Date:  2010-10-07

9.  Weight gain in pregnancy and risk of maternal hyperglycemia.

Authors:  Sharon J Herring; Emily Oken; Sheryl L Rifas-Shiman; Janet W Rich-Edwards; Alison M Stuebe; Ken P Kleinman; Matthew W Gillman
Journal:  Am J Obstet Gynecol       Date:  2009-04-15       Impact factor: 8.661

10.  First-trimester fasting hyperglycemia and adverse pregnancy outcomes.

Authors:  Shlomit Riskin-Mashiah; Grace Younes; Amit Damti; Ron Auslender
Journal:  Diabetes Care       Date:  2009-06-23       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.